Report cover image

Pericarditis Treatment Market

Publisher Future Market Insights
Published Jun 23, 2022
Length 299 Pages
SKU # FMARI17949492

Description

Pericarditis Treatment Market


Global Pericarditis Treatment: Market Insights 

Pericarditis is a cardiovascular disease which represents the swelling of the pericardium wall of the heart. The main cause of pericardium disease is the inflammation of pericardium wall which is generally caused by viral infection. Other causes of pericarditis disease are renal failure, bacterial infections and intake of some drugs such as procainamide.

Some of the common symptoms of pericarditis disease are shortness of breath, fatigue, rapid or abnormal heart rhythms, and chest pain. Global Pericarditis treatment includes therapeutic treatment and surgical treatment. Acute pericarditis can be treated by medication for pain and inflammation, such as aspirin and ibuprofen. Depending on the cause of the pericarditis disease, several antifungal medications are prescribed which are expected to hold the maximum revenue in the pericarditis treatment market. In case of chronic or recurrent pericarditis, anti-inflammatory drugs such as colchicine are prescribed for pericarditis treatment. If the patient suffering from pericarditis disease does not show any response to the anti-inflammatory drugs, they are prescribed with corticosteroids such as prednisone.

Apart from medications, there are other surgical methods of treatment in pericarditis treatment market which are needed in the patients especially when all the other medical treatment fails. 

Global Pericarditis Treatment: Market Dynamics

Increase in the prevalence rate of cardiovascular diseases across the globe is the major growth driver of Global Pericarditis Treatment Market. The growing geriatric population is also responsible for the growth of pericarditis treatment market. Increase in smoking, alcohol consumption, and lifestyle changes are the major factor behind the growth in cardiovascular diseases and also contributing factor for the growth of the pericarditis treatment market. More focus on the prevention and treatment of cardiovascular diseases in low- and middle-income economies is expected to drive the growth of the market for Pericarditis treatment. Increasing healthcare expenditures is also expected to fuel the global pericarditis treatment market.

Lack of awareness and the high cost of surgeries are the major factors which can hamper the growth of the Global Pericarditis Treatment Market. 

Global Pericarditis Treatment: Segmentation

The Global Pericarditis Treatment market is segmented by Disease type, Treatment type and End user:

By Disease Type

Acute Pericarditis

Chronic Pericarditis

Recurrent Pericarditis

Idiopathic Pericarditis 

By Treatment

Therapeutics

Nonsteroidal anti-inflammatory drugs (NSAIDs)

Antibiotic/Antifungal Medication

Corticosteroids

Surgery

Pericardiectomy

Pericardiocentesis

Pericardiotomy 

End Users

Hospitals

Clinics

Ambulatory Surgical Centers

Academic & Research Institutes 

Global Pericarditis Treatment Market : Overview 

Pericarditis treatment has been segmented into therapeutics and surgery. Pericarditis therapeutics include medication for pain and inflammation, such as aspirin and ibuprofen. Antibiotic or antifungal medicines are majorly used to treat the pericarditis disease and are expected to hold the maximum revenue share in the global pericarditis treatment market. Anti-inflammatory drugs such as colchicine are also used for the treatment of pericarditis disease.

Surgery is not a usual way of treatment and they are adopted only if the other methods of treatment are not successful. 

Global Pericarditis Treatment Market: Region-wise Outlook 

On the basis of geography, Global Pericarditis Treatment Market is segmented into seven key regions viz. North America, Latin America, Western Europe, Eastern Europe, the Asia Pacific excluding Japan, Japan, and Middle East & Africa. North America is expected to hold largest shares in the Pericarditis Treatment Market primarily due to the presence of a large number of hospitals and high-quality healthcare infrastructure. North America has a high number of laboratories for clinical research, therefore, is expected to drive the global pericarditis treatment market. Europe is expected to show the second highest share in Pericarditis Treatment market due to high prevalence of cardiovascular diseases. The Asia Pacific is also expected to hold a large revenue share in the global pericarditis treatment market due to the presence of a large population and a huge occurrence of cardiovascular diseases.   

Global Pericarditis Treatment Market: Key Players 

Global Pericarditis treatment market has many key players. Major international manufacturers leading Pericarditis Treatment Market are Pfizer Inc., Bayer AG, PerkinElmer Inc., ALLERGAN, Lincoln Pharmaceuticals Ltd., Unicure India Pvt. Ltd., Zydus Cadila Healthcare Ltd., Twilight Mercantiles Pvt. Ltd.,Aasraw Biochemical Technology Co.ltd, Sun Pharmaceutical Industries Ltd. 

The report covers exhaustive analysis on:

Pericarditis Treatment Market Segments

Pericarditis Treatment Market Dynamics

Pericarditis Treatment Market Size

Current Trends/Issues/Challenges

Competition & Companies involved

Value Chain

 The regional analysis includes:

North America (U.S., Canada)

Latin America (Mexico. Brazil)

Western Europe (Germany, Italy, France, U.K, Spain, Nordic countries, Belgium, Netherlands, Luxembourg)

Eastern Europe (Poland, Russia)

Asia-Pacific Excluding Japan (China, India, ASEAN, Australia & New Zealand)

Japan

The Middle East and Africa (GCC, S. Africa, N. Africa) 

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macroeconomic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies. 

Report Highlights:

Detailed overview of parent market

Changing Pericarditis Treatment market dynamics in the industry

In-depth Pericarditis Treatment market segmentation

Historical, current and projected market size in terms of volume and value

Recent industry trends and developments

Competitive landscape

Strategies of key players and products offered

Potential and niche segments, geographical regions exhibiting promising growth

A neutral perspective on market performance

NOTE - All statements of fact, opinion, or analysis expressed in reports are those of the respective analysts. They do not necessarily reflect formal positions or views of Future Market Insights.

Table of Contents

299 Pages
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. Value Chain Analysis
   3.5.1. Profit Margin Analysis
   3.5.2. Service Providers
3.6. PESTLE and Porter’s Analysis
3.7. Regulatory Landscape
   3.7.1. By Key Regions
   3.7.2. By Key Countries
3.8. Regional Parent Market Outlook
4. Global Pericarditis Treatment Market Analysis 2017-2021 and Forecast, 2022-2032
4.1. Historical Market Size Value (US$ Mn) Analysis, 2017-2021
4.2. Current and Future Market Size Value (US$ Mn) Projections, 2022-2032
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Pericarditis Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Disease Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Mn) Analysis By Disease Type, 2017-2021
5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Disease Type, 2022-2032
5.3.1. Acute Pericarditis
5.3.2. Chronic Pericarditis
5.3.3. Recurrent Pericarditis
5.3.4. Idiopathic Pericarditis
5.4. Y-o-Y Growth Trend Analysis By Disease Type, 2017-2021
5.5. Absolute $ Opportunity Analysis By Disease Type, 2022-2032
6. Global Pericarditis Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Treatment
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Mn) Analysis By Treatment, 2017-2021
6.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Treatment, 2022-2032
6.3.1. Therapeutics
6.3.2. Nonsteroidal Anti-inflammatory Drugs
6.3.3. Antibiotic/Antifungal Medication
6.3.4. Corticosteroids
6.3.5. Surgery
6.3.6. Pericardiectomy
6.3.7. Pericardiocentesis
6.3.8. Pericardiotomy
6.4. Y-o-Y Growth Trend Analysis By Treatment, 2017-2021
6.5. Absolute $ Opportunity Analysis By Treatment, 2022-2032
7. Global Pericarditis Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By End Users
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Mn) Analysis By End Users, 2017-2021
7.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By End Users, 2022-2032
7.3.1. Hospitals
7.3.2. Clinics
7.3.3. Ambulatory Surgical Centers
7.3.4. Academic & Research Institutes
7.4. Y-o-Y Growth Trend Analysis By End Users, 2017-2021
7.5. Absolute $ Opportunity Analysis By End Users, 2022-2032
8. Global Pericarditis Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2017-2021
8.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2022-2032
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. East Asia
8.3.5. South Asia & Pacific
8.3.6. MEA
8.4. Market Attractiveness Analysis By Region
9. North America Pericarditis Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Country
9.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
9.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
9.2.1. By Country
9.2.1.1. U.S.
9.2.1.2. Canada
9.2.2. By Disease Type
9.2.3. By Treatment
9.2.4. By End Users
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Disease Type
9.3.3. By Treatment
9.3.4. By End Users
9.4. Key Takeaways
10. Latin America Pericarditis Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Country
10.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
10.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
10.2.1. By Country
10.2.1.1. Mexico
10.2.1.2. Brazil
10.2.1.3. Rest of Latin America
10.2.2. By Disease Type
10.2.3. By Treatment
10.2.4. By End Users
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Disease Type
10.3.3. By Treatment
10.3.4. By End Users
10.4. Key Takeaways
11. Europe Pericarditis Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Country
11.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
11.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. Italy
11.2.1.3. France
11.2.1.4. U.K.
11.2.1.5. Spain
11.2.1.6. BENELUX
11.2.1.7. Russia
11.2.1.8. Rest of Europe
11.2.2. By Disease Type
11.2.3. By Treatment
11.2.4. By End Users
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Disease Type
11.3.3. By Treatment
11.3.4. By End Users
11.4. Key Takeaways
12. East Asia Pericarditis Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Country
12.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
12.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
12.2.1. By Country
12.2.1.1. China
12.2.1.2. Japan
12.2.1.3. South Korea
12.2.2. By Disease Type
12.2.3. By Treatment
12.2.4. By End Users
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Disease Type
12.3.3. By Treatment
12.3.4. By End Users
12.4. Key Takeaways
13. South Asia & Pacific Pericarditis Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Country
13.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
13.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
13.2.1. By Country
13.2.1.1. India
13.2.1.2. ASEAN
13.2.1.3. Australia and New Zealand
13.2.1.4. Rest of South Asia & Pacific
13.2.2. By Disease Type
13.2.3. By Treatment
13.2.4. By End Users
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Disease Type
13.3.3. By Treatment
13.3.4. By End Users
13.4. Key Takeaways
14. MEA Pericarditis Treatment Market Analysis 2017-2021 and Forecast 2022-2032, By Country
14.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
14.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2022-2032
14.2.1. By Country
14.2.1.1. GCC Countries
14.2.1.2. Turkey
14.2.1.3. South Africa
14.2.1.4. Rest of MEA
14.2.2. By Disease Type
14.2.3. By Treatment
14.2.4. By End Users
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Disease Type
14.3.3. By Treatment
14.3.4. By End Users
14.4. Key Takeaways
15. Key Countries Pericarditis Treatment Market Analysis
15.1. U.S.
15.1.1. Pricing Analysis
15.1.2. Market Share Analysis, 2021
15.1.2.1. By Disease Type
15.1.2.2. By Treatment
15.1.2.3. By End Users
15.2. Canada
15.2.1. Pricing Analysis
15.2.2. Market Share Analysis, 2021
15.2.2.1. By Disease Type
15.2.2.2. By Treatment
15.2.2.3. By End Users
15.3. Mexico
15.3.1. Pricing Analysis
15.3.2. Market Share Analysis, 2021
15.3.2.1. By Disease Type
15.3.2.2. By Treatment
15.3.2.3. By End Users
15.4. Brazil
15.4.1. Pricing Analysis
15.4.2. Market Share Analysis, 2021
15.4.2.1. By Disease Type
15.4.2.2. By Treatment
15.4.2.3. By End Users
15.5. Germany
15.5.1. Pricing Analysis
15.5.2. Market Share Analysis, 2021
15.5.2.1. By Disease Type
15.5.2.2. By Treatment
15.5.2.3. By End Users
15.6. Italy
15.6.1. Pricing Analysis
15.6.2. Market Share Analysis, 2021
15.6.2.1. By Disease Type
15.6.2.2. By Treatment
15.6.2.3. By End Users
15.7. France
15.7.1. Pricing Analysis
15.7.2. Market Share Analysis, 2021
15.7.2.1. By Disease Type
15.7.2.2. By Treatment
15.7.2.3. By End Users
15.8. U.K.
15.8.1. Pricing Analysis
15.8.2. Market Share Analysis, 2021
15.8.2.1. By Disease Type
15.8.2.2. By Treatment
15.8.2.3. By End Users
15.9. Spain
15.9.1. Pricing Analysis
15.9.2. Market Share Analysis, 2021
15.9.2.1. By Disease Type
15.9.2.2. By Treatment
15.9.2.3. By End Users
15.10. BENELUX
15.10.1. Pricing Analysis
15.10.2. Market Share Analysis, 2021
15.10.2.1. By Disease Type
15.10.2.2. By Treatment
15.10.2.3. By End Users
15.11. Russia
15.11.1. Pricing Analysis
15.11.2. Market Share Analysis, 2021
15.11.2.1. By Disease Type
15.11.2.2. By Treatment
15.11.2.3. By End Users
15.12. China
15.12.1. Pricing Analysis
15.12.2. Market Share Analysis, 2021
15.12.2.1. By Disease Type
15.12.2.2. By Treatment
15.12.2.3. By End Users
15.13. Japan
15.13.1. Pricing Analysis
15.13.2. Market Share Analysis, 2021
15.13.2.1. By Disease Type
15.13.2.2. By Treatment
15.13.2.3. By End Users
15.14. South Korea
15.14.1. Pricing Analysis
15.14.2. Market Share Analysis, 2021
15.14.2.1. By Disease Type
15.14.2.2. By Treatment
15.14.2.3. By End Users
15.15. India
15.15.1. Pricing Analysis
15.15.2. Market Share Analysis, 2021
15.15.2.1. By Disease Type
15.15.2.2. By Treatment
15.15.2.3. By End Users
15.16. ASEAN
15.16.1. Pricing Analysis
15.16.2. Market Share Analysis, 2021
15.16.2.1. By Disease Type
15.16.2.2. By Treatment
15.16.2.3. By End Users
15.17. Australia and New Zealand
15.17.1. Pricing Analysis
15.17.2. Market Share Analysis, 2021
15.17.2.1. By Disease Type
15.17.2.2. By Treatment
15.17.2.3. By End Users
15.18. GCC Countries
15.18.1. Pricing Analysis
15.18.2. Market Share Analysis, 2021
15.18.2.1. By Disease Type
15.18.2.2. By Treatment
15.18.2.3. By End Users
15.19. Turkey
15.19.1. Pricing Analysis
15.19.2. Market Share Analysis, 2021
15.19.2.1. By Disease Type
15.19.2.2. By Treatment
15.19.2.3. By End Users
15.20. South Africa
15.20.1. Pricing Analysis
15.20.2. Market Share Analysis, 2021
15.20.2.1. By Disease Type
15.20.2.2. By Treatment
15.20.2.3. By End Users
16. Market Structure Analysis
16.1. Competition Dashboard
16.2. Competition Benchmarking
16.3. Market Share Analysis of Top Players
16.3.1. By Regional
16.3.2. By Disease Type
16.3.3. By Treatment
16.3.4. By End Users
17. Competition Analysis
17.1. Competition Deep Dive
17.1.1. Pfizer Inc.
17.1.1.1. Overview
17.1.1.2. Product Portfolio
17.1.1.3. Profitability by Market Segments
17.1.1.4. Sales Footprint
17.1.1.5. Strategy Overview
17.1.1.5.1. Marketing Strategy
17.1.1.5.2. Product Strategy
17.1.1.5.3. Channel Strategy
17.1.2. Bayer AG
17.1.2.1. Overview
17.1.2.2. Product Portfolio
17.1.2.3. Profitability by Market Segments
17.1.2.4. Sales Footprint
17.1.2.5. Strategy Overview
17.1.2.5.1. Marketing Strategy
17.1.2.5.2. Product Strategy
17.1.2.5.3. Channel Strategy
17.1.3. PerkinElmer Inc.
17.1.3.1. Overview
17.1.3.2. Product Portfolio
17.1.3.3. Profitability by Market Segments
17.1.3.4. Sales Footprint
17.1.3.5. Strategy Overview
17.1.3.5.1. Marketing Strategy
17.1.3.5.2. Product Strategy
17.1.3.5.3. Channel Strategy
17.1.4. ALLERGAN
17.1.4.1. Overview
17.1.4.2. Product Portfolio
17.1.4.3. Profitability by Market Segments
17.1.4.4. Sales Footprint
17.1.4.5. Strategy Overview
17.1.4.5.1. Marketing Strategy
17.1.4.5.2. Product Strategy
17.1.4.5.3. Channel Strategy
17.1.5. Lincoln Pharmaceuticals Ltd.
17.1.5.1. Overview
17.1.5.2. Product Portfolio
17.1.5.3. Profitability by Market Segments
17.1.5.4. Sales Footprint
17.1.5.5. Strategy Overview
17.1.5.5.1. Marketing Strategy
17.1.5.5.2. Product Strategy
17.1.5.5.3. Channel Strategy
17.1.6. Unicure India Pvt. Ltd.
17.1.6.1. Overview
17.1.6.2. Product Portfolio
17.1.6.3. Profitability by Market Segments
17.1.6.4. Sales Footprint
17.1.6.5. Strategy Overview
17.1.6.5.1. Marketing Strategy
17.1.6.5.2. Product Strategy
17.1.6.5.3. Channel Strategy
17.1.7. Zydus Cadila Healthcare Ltd.
17.1.7.1. Overview
17.1.7.2. Product Portfolio
17.1.7.3. Profitability by Market Segments
17.1.7.4. Sales Footprint
17.1.7.5. Strategy Overview
17.1.7.5.1. Marketing Strategy
17.1.7.5.2. Product Strategy
17.1.7.5.3. Channel Strategy
17.1.8. Aasraw Biochemical Technology Co.ltd
17.1.8.1. Overview
17.1.8.2. Product Portfolio
17.1.8.3. Profitability by Market Segments
17.1.8.4. Sales Footprint
17.1.8.5. Strategy Overview
17.1.8.5.1. Marketing Strategy
17.1.8.5.2. Product Strategy
17.1.8.5.3. Channel Strategy
17.1.9. Sun Pharmaceutical Industries Ltd
17.1.9.1. Overview
17.1.9.2. Product Portfolio
17.1.9.3. Profitability by Market Segments
17.1.9.4. Sales Footprint
17.1.9.5. Strategy Overview
17.1.9.5.1. Marketing Strategy
17.1.9.5.2. Product Strategy
17.1.9.5.3. Channel Strategy
18. Assumptions & Acronyms Used
19. Research Methodology

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us